Press releases - UCB
Oct 9, 2024 · UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting. Read More.
Newsroom - UCB
UCB on YouTube. More videos. Resources. Access our media image selection or contact us for particular requests. View all resources. Contact. The UCB media relations team responds to calls and emails from professional journalists only. Contact us. Choose a Country.
UCB and Biogen Announce Positive Topline Results From Phase 3 …
Sep 24, 2024 · UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024. Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical …
UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab …
Sep 23, 2024 · With three new indications, BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases.
UCB Announces Bepranemab Phase 2a Study Results Accepted for …
3 days ago · UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting. Bepranemab - an investigational anti-tau antibody - targeting the mid-region of the tau protein is being studied to assess its potential to delay Alzheimer’s disease progression 1.
UCB Receives New European Commission Approvals for BIMZELX ...
Jun 7, 2023 · These approvals in the European Union (EU) represent the first marketing authorizations for bimekizumab in PsA and axSpA worldwide, and the second and third indications for bimekizumab in the EU, following its approval for the treatment of moderate to severe plaque psoriasis in August 2021.1. “The European Commission’s parallel approval of ...
UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for …
Oct 17, 2023 · With the FDA approval of zilucoplan, and with RYSTIGGO ® (rozanolixizumab-noli) already FDA approved and launched in the U.S 3, UCB is the first organization to offer the U.S. gMG community the opportunity to benefit from a choice of two new targeted therapies from a single company.
Home | UCB
Oct 16, 2024 · At UCB, we believe that everyone deserves to live the best life that they can. That’s why – as a global biopharmaceutical leader - we’re focused on creating valuable solutions that make improvements to the lives of people living with neurological and autoimmune conditions now and into the future.
UCB - sustaining growth, now and into the future
UCB will continue to advance its late stage development pipeline and prepare upcoming launches to offer potential new solutions for patients. Underlying profitability, adjusted EBITDA, is expected in the range of 27 - 28% of revenue, reflecting the high R&D and …
UCB expands innovation footprint with new state-of-the-art gene …
Brussels (Belgium), 8th March 2022, 07:00 (CET) – UCB, a global biopharmaceutical company, today announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine l’Alleud, Wallonia, Belgium. The new facility, representing an ...